Capital Research Global Investors Increases Position in Cencora, Inc. $COR

Capital Research Global Investors lifted its position in Cencora, Inc. (NYSE:COR) by 3.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,749,577 shares of the company’s stock after purchasing an additional 88,544 shares during the period. Capital Research Global Investors’ holdings in Cencora were worth $928,670,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Oakworth Capital Inc. purchased a new stake in shares of Cencora in the fourth quarter worth $26,000. Elyxium Wealth LLC purchased a new stake in shares of Cencora in the fourth quarter worth $27,000. Archer Investment Corp increased its stake in shares of Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after purchasing an additional 47 shares in the last quarter. IAG Wealth Partners LLC purchased a new stake in shares of Cencora in the third quarter worth $30,000. Finally, Caitlin John LLC purchased a new stake in shares of Cencora in the third quarter worth $31,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Performance

COR opened at $274.94 on Friday. The stock has a market capitalization of $53.49 billion, a price-to-earnings ratio of 21.08, a PEG ratio of 1.48 and a beta of 0.59. The company has a fifty day moving average of $292.70 and a 200 day moving average of $330.55. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). The company had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business’s revenue was up 3.9% on a year-over-year basis. During the same period in the previous year, the business posted $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, sell-side analysts forecast that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora declared that its board has approved a stock buyback plan on Thursday, May 21st that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the company to reacquire up to 3.9% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s leadership believes its shares are undervalued.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s dividend payout ratio (DPR) is presently 18.40%.

Analyst Upgrades and Downgrades

COR has been the subject of a number of analyst reports. William Blair initiated coverage on shares of Cencora in a research note on Tuesday, April 28th. They issued a “market perform” rating for the company. Leerink Partners reissued an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Wells Fargo & Company reduced their price objective on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a research note on Monday, May 11th. JPMorgan Chase & Co. raised their target price on shares of Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. Finally, Morgan Stanley set a $342.00 target price on shares of Cencora in a research note on Friday, May 8th. Twelve research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $380.25.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.